Drug Development for Alzheimer's Disease: Recent Progress

Alzheimer's disease, the most common cause of dementia, is characterized by two major pathological hallmarks: amyloid plaques and neurofibrillary tangles. Based on these two indicators, an amyloid cascade hypothesis was proposed, and accordingly, most current therapeutic approaches are now focused on the removal of β-amyloid peptides (Aβ from the brain. Additionally, strategies for blocking tau hyperphosphorylation and aggregation have been suggested, including the development of drugs that can block the formation of tangles. However, there are no true disease-modifying drugs in the current market, though many drugs based on theories other than Aβ and tau pathology are under development. The purpose of this review was to provide information on the current development of AD drugs and to discuss the issues related to drug development

Clinical trials and late-stage drug development in Alzheimer’s disease: An appraisal from 1984 to 2014

The modern era of drug development for Alzheimer\u27s disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research criteria for Alzheimer\u27s disease. Since then, despite the evaluation of numerous potential treatments in clinical trials, only four cholinesterase inhibitors and memantine have shown sufficient safety and efficacy to allow marketing approval at an international level. Although this is probably because the other drugs tested were ineffective, inadequate clinical development methods have also been blamed for the failures. Here, we review the development of treatments for Alzheimer\u27s disease during the past 30 years, considering the drugs, potential targets, late‐stage clinical trials, development methods, emerging use of biomarkers and evolution of regulatory considerations in order to summarize advances and anticipate future developments. We have considered late‐stage Alzheimer\u27s disease drug development from 1984 to 2013, including individual clinical trials, systematic and qualitative reviews, meta‐analyses, methods, commentaries, position papers and guidelines. We then review the evolution of drugs in late clinical development, methods, biomarkers and regulatory issues. Although a range of small molecules and biological products against many targets have been investigated in clinical trials, the predominant drug targets have been the cholinergic system and the amyloid cascade. Trial methods have evolved incrementally: inclusion criteria have largely remained focused on mild‐to‐moderate Alzheimer\u27s disease criteria, recently extending to early or prodromal Alzheimer disease or ‘mild cognitive impairment due to Alzheimer\u27s disease’, for drugs considered to be disease modifying. The duration of trials has remained at 6–12 months for drugs intended to improve symptoms; 18‐ to 24‐month trials have been established for drugs expected to attenuate clinical course. Cognitive performance, activities of daily living, global change and severity ratings have persisted as the primary clinically relevant outcomes. Regulatory guidance and oversight have evolved to allow for enrichment of early‐stage Alzheimer\u27s disease trial samples using biomarkers and phase‐specific outcomes. In conclusion, validated drug targets for Alzheimer\u27s disease remain to be developed. Only drugs that affect an aspect of cholinergic function have shown consistent, but modest, clinical effects in late‐phase trials. There is opportunity for substantial improvements in drug discovery and clinical development methods

A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity

Non-steroidal anti-inflammatory drugs (NSAIDs) represent a diverse class of drugs and are among the most commonly used analgesics for arthritic pain worldwide, though long-term use is associated with a spectrum of adverse effects. The introduction of cyclooxygenase-2-selective NSAIDs early in the last decade offered an alternative to traditional NSAIDs with similar efficacy and improved gastrointestinal tolerability; however, emerging concerns about cardiovascular safety resulted in the withdrawal of two agents (rofecoxib and valdecoxib) in the mid-2000s and, subsequently, in an overall reduction in NSAID use. It is now understood that all NSAIDs are associated with some varying degree of gastrointestinal and cardiovascular risk. Guidelines still recommend their use, but little is known of how patients use these agents. While strategies and guidelines aimed at reducing NSAID-associated complications exist, there is a need for evidence-based algorithms combining cardiovascular and gastrointestinal factors that can be used to aid treatment decisions at an individual patient level

Estudio epidemiológico de la prevalencia e identificación de parásitos gastrointestinales en terneros de 2 a 6 meses de edad del municipio de San Pedro de Lóvago - Chontales

El presente estudio se realizó con el objetivo determinar la prevalencia e identificación de los principales parásitos gastrointestinales en terneros de 2 a 6 meses de edad en las fincas del Municipio de San Pedro de Lóvago – Chontales, El municipio se localiza entre las coordenadas 12º 07 ́ latitud norte y 85º07 ́ latitud oeste. La altitud promedio es de 340 msnm. La temperatura promedio anual oscila entre los 25 y 26ºC; su precipitación pluvial varía entre los 1,200 y 1,400mm al año. Para determinar el tamaño de la muestra se utilizó la formula de Martinet al.(1987) y Trusfield, (1995) donde plantean que N = 1,962* p *q / L 2, donde p es la prevalencia, q = 1–p y L especifica el límite deseado de error de la prevalencia. Se espera que la prevalencia (p) de 50% sea usada en combinación con él límite deseado de error de 14%, si la prevalencia en la población entera es desconocida. El tamaño requerido de la muestra de éste trabajo, fue de 84 fincas examinando el 20% de los terneros de cada población de toda la zona en estudio. Los resultados obtenidos, se identificaron dos géneros de parásitos. De los cuales 1 es de La Clase Protozoario y 1 de La Clase Nematodo, entre ellos se encontró al género Strongyloides spp y Coccideas spp, por orden de importancia y presentación. De un total de 84 fincas estudiadas, se examinaron 646 animales, obteniéndose 183 animales positivos representando el 28.3 % de prevalencia y 463 negativos para un 71.7% respectivamente. De los 183 animales que resultaron positivos se encontró que 27 animales presentaban el género Coccideas spp representando un nivel medio de infestacion 405 hpg y 156 animales con el género Strongyloides spp representando un nivel medio de infestacion de 385hpg